The global herpes labialis treatment market is estimated to be valued at USD 1,238.7 million in 2025 and is projected to reach USD 1,887.1 million by 2035, registering a CAGR of 4.3% over the forecast ...

Herpes simplex virus type I (HSV-1) is a member of the α-herpesvirus subfamily and is capable of causing herpes simplex keratitis, herpes labialis, and herpes simplex encephalitis. HSV-1 is well known ...

The herpes labialis treatment market is highly competitive, and market players are developing new items to tighten their hold on the market by using several technical advancements. In addition, ...

The herpes simplex virus is classified into type 1 (HSV-1, herpes labialis) and type 2 (HSV-2, herpes genitalis). Infections caused by these viruses are further divided into primary and secondary ...

Herpes labialis infection is currently incurable, and available therapies mainly aim to alleviate symptoms and lessen the frequency and intensity of outbreaks. As a result, there is a sizable unmet ...

In a nested randomized controlled trial (RCT) published in eClinicalMedicine, researchers examined the effect of Bacillus Calmette-Guérin (BCG) vaccination on attenuating herpes labialis (cold ...

Saint Paul, Minnesota-based Squarex Pharmaceutical Corporation was founded to develop a cold sore treatment drug for herpes simplex with a goal to also investigate treatment of herpes labialis.

Penciclovir cream is indicated for the treatment of recurrent cold sores (herpes labialis) on the lips and face of adults and children aged 12 years old and older.

An alternative treatment for herpes labialis infection is the diode laser. This treatment option alters cell and tissue function, and decreases healing time. The laser energy kills the surface virus, ...